Raymond James Financial Inc Verve Therapeutics, Inc. Transaction History
Raymond James Financial Inc
- $299 Billion
- Q3 2025
Shares
2 transactions
Others Institutions Holding VERV
# of Institutions
20Shares Held
8.52MCall Options Held
2.9KPut Options Held
37.1K-
Black Rock Inc. New York, NY6.62MShares$73.7 Million0.0% of portfolio
-
Nuveen Asset Management, LLC Chicago, IL1.32MShares$14.6 Million0.0% of portfolio
-
Wade G W & Inc Wellesley, MA260KShares$2.89 Million0.12% of portfolio
-
Xtx Topco LTD London, X0125KShares$1.39 Million0.08% of portfolio
-
Credit Suisse Ag Zurich, V865.7KShares$731,7080.0% of portfolio
About Verve Therapeutics, Inc.
- Ticker VERV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,942,300
- Market Cap $667M
- Description
- Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...